Entecavir (ETV) demonstrates consistent responses throughout baseline demographic subgroups for the treatment of nucleosidenaive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B
Yazar
Klesezewski, K
Apelian, D
Fernandes, L
Cross, A
Wilber, R
Shouval, D
Senturk, H
Gish, RG
Chang, TT
Yurdaydin, C
Lai, CL
Lok, AS
Brown, RS
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Bildiri [64839]